Osteofibrous Dysplasia (Kempson-Campanacci's Disease)
Launched by ISTITUTO ORTOPEDICO RIZZOLI · Sep 24, 2019
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female patients treated at Rizzoli Institute from 01 Jan 1943 to 31 Dic 2011
- • Diagnosis of osteofibrous dysplasia pathologically confirmed
- • Written informed consent prior to any study-specific analysis and/or data collection
- Exclusion Criteria:
- • Patients with histological diagnosis different from osteofibrous dysplasia
About Istituto Ortopedico Rizzoli
Istituto Ortopedico Rizzoli is a renowned orthopedic research and treatment institute based in Bologna, Italy, dedicated to advancing musculoskeletal health through innovative clinical trials and cutting-edge medical practices. With a strong emphasis on research, the institute collaborates with leading experts in orthopedics, rehabilitation, and related fields to develop and evaluate new therapies and surgical techniques. Committed to improving patient outcomes, Istituto Ortopedico Rizzoli not only focuses on high-quality clinical care but also fosters a robust research environment that supports the translation of scientific findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials